5.3.2 Herpes virus infections - North & East

All information is correct at time of printing and is subject to change without notice. The Devon Formulary and Referral Website is not in any way liable for the accuracy of any information printed and stored by users. For the most up-to-date information, please refer to the website.

Switch to S&W website

Formulary

Back

5.3 Antiviral drugs Toggle Pages

5.3.1 HIV infection 5.3.2 Herpes virus infections 5.3.3 Viral hepatitis 5.3.4 Influenza 5.3.5 Respiratory syncytial virus (RSV) 5.3.6 nMABs and other antiviral drugs

Chapter 5: Infections Toggle Parent Pages

Principles of antibacterial treatment Upper respiratory tract infections Lower respiratory tract infections Acute exacerbation of bronchiectasis (non-cystic fibrosis) Urinary tract infections (UTI) Gastro-intestinal tract infections Genital tract infections Meningitis Skin and soft tissue infections Lyme disease Eye infections Oral and dental infections COVID-19 treatments for patients who do not require hospitalisation 5.1 Antibacterial drugs 5.2 Antifungal drugs 5.3 Antiviral drugs 5.4 Antiprotozoal drugs 5.5 Anthelmintics

Print this page

Contact us about this page

5.3.2 Herpes virus infections

First Line

Second Line

Specialist

Hospital Only

5.3.2.1 Herpes simplex and varicella-zoster infection

Aciclovir

Tablets 200mg, 400mg, 800mg (£0.54, £0.48, £0.99 = (price for guide only) 10 tablets)
Dispersible tablets 200mg, 400mg, 800mg (£0.74, £1.60, £2.65 = (price for guide only) 10 tablets)
Intravenous infusion 250mg/10ml, 500mg/20ml, 1g/40ml (see note 1)

Indications

Notes

For intravenous administration, refer to the manufacturer's Summary of Product Characteristics (SPC) or the BNF for the dose according to indication as the oral and intravenous doses differ

5.3.2.2 Cytomegalovirus

Letermovir

Tablets 240mg

Notes

NICE TA591: Letermovir (Prevymis) is recommended as an option for preventing cytomegalovirus (CMV) reactivation and disease after an allogeneic haematopoietic stem cell transplant (HSCT) in adults who are seropositive for CMV (July 2019)

Maribavir

Tablets 200mg

Notes

NICE TA860: Maribavir (Livtencity) is recommended, within its marketing authorisation, as an option for treating cytomegalovirus (CMV) infection that is refractory to treatment including cidofovir, foscarnet, ganciclovir or valganciclovir in adults who have had a haematopoietic stem cell transplant or solid organ transplant, only if the company provides it according to the commercial arrangement (January 2023).